Efficacy and safety of febuxostat in renal transplant recipients with hyperuricemia

2019 
Objective To assess the efficacy and safety of febuxostat in the treatment of hyperuricemia in renal transplant recipients. Methods A total of 124 renal transplant patients with hyperuricemia receiving febuxostat between June 2016 and July 2018 were retrospectively analyzed. Uric acid (UA), liver function and renal function parameters before and 3 months after treatment were compared. Adverse events, recipient and renal allograft survival were recorded throughout the follow-up period. Results Serum level of uric acid significantly decreased after 3-month treatment (P<0.001). And 66.1 % of them achieved target UA level at Month 3 after dosing. Estimated glomerular filtration rate (eGFR) was maintained. No severe adverse event was observed. All recipient and renal grafts survived during the follow-up period. Conclusions Febuxostat is both effective and safe in the treatment of hyperuricemia in renal transplant. Key words: Renal transplantation; Hyperuricemia; Efficacy
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    1
    Citations
    NaN
    KQI
    []